New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
07:52 EDTABBV, PCYCPharmacyclics superior safey profile improves outlook in CLL, says RBC Capital
After another patient died after using AbbVie's (ABBV) ABT-199, RBC Capital believes that widespread use of the drug is probably not as likely as some AbbVie bulls believe. The firm expects Pharmacyclics' (PCYC) stock to be strengthened by the news, as RBC thinks the superior safety profile of that company's CLL treatment enhances its position as a treatment for the disease. The firm keeps an Outperform rating on Pharmacyclics.
News For PCYC;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
14:32 EDTPCYC, ABBVPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
09:05 EDTPCYCPharmacyclics reports positive data suggesting ibrutinib is an effective option
Ibrutinib data presented yesterday by Pharmacyclics at the American Association for Cancer Research, or AACR, Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft mice. These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
08:47 EDTPCYCPharmacyclics announces positive results from PCYC-1102 study
Pharmacyclics announced that IMBRUVICA follow-up data in treatment-naive, or TN, and relapsed/refractory patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL and SLL respectively, demonstrated that, with up to 45 months of follow-up, the 94 patients who received IMBRUVICA 420 mg experienced a 91% overall response rate, or ORR, and 14% of all patients achieved a complete response. These data are an analysis of outcomes from the Phase I/IIb study, or PCYC-1102, and the ongoing extension study and were presented in an oral presentation at the American Association of Cancer Research.
07:20 EDTABBVAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTABBVAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
16:50 EDTABBV, PCYCAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
April 13, 2015
14:07 EDTABBV, PCYCEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 9, 2015
09:10 EDTPCYCPharmacyclics' Imbruvica shows positive Phase II data
Subscribe for More Information
April 8, 2015
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use